Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advair Bioequivalence Guidance Falls Short of GSK’s Requests

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.

You may also be interested in...



Generic Advair's Labeling Variation Stems From Permissible Design Differences, US FDA Says

Patient instructions for use of Mylan’s fluticasone/salmeterol generic are noticeably different from GSK’s reference listed drug but fall within the ‘different manufacturers’ exception to the ‘same labeling’ requirement.

Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs

The latest drug development news and highlights from our US FDA Performance Tracker.

CEO Shifts, Life Cycle Management On Agenda at Morgan Stanley

The Morgan Stanley Healthcare Conference attracted top management from big pharma, biotech and specialty firms, with Sanofi’s Elias Zerhouni commenting on the company’s strategy in Gaucher’s disease and Mylan expressing confidence in its ability to deliver on a generic Advair that meets FDA’s newly-issued proposed standards for substitutability.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel